Oxygenta Pharmaceutical (524636) Q1 25/26 earnings summary

Executive summary

• Board approved unaudited financial results for the quarter ended 30 June 2025 and noted limited review by statutory auditors.

• Appointments of internal, secretarial, and cost auditors for FY 2025-26 were confirmed.

• Company Secretary & Compliance Officer resigned and a new appointment was made effective 14 August 2025.

Financial highlights

• Total revenue for Q1 FY26 was ₹1,513.47 lakhs, up from ₹1,262.08 lakhs in Q1 FY25.

• Net loss for Q1 FY26 stood at ₹610.61 lakhs, compared to a net loss of ₹136.33 lakhs in Q1 FY25.

• Loss before tax for Q1 FY26 was ₹814.80 lakhs, higher than ₹281.70 lakhs in Q1 FY25.

• Basic and diluted EPS for Q1 FY26 was (₹1.65), compared to (₹0.39) in Q1 FY25.

Outlook and guidance

• Company is prioritizing compliance and transparency, especially regarding MSME creditor identification and bill-to-bill adjustment processes.